Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.
De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.
De Remigis A, et al.
Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.
Int J Cancer. 2015.
PMID: 24832153
Free PMC article.